xk469
Small moleculeexperimental
Clinical trial activity
3 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Dec 1, 2001 (NCT00028522)
Timeline
2000s
- Jan 1, 2001
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
- Anemia, Refractory · Phase 1
- Leukemia · Phase 1
- Leukemia, Eosinophilic, Acute · Phase 1
- Leukemia, Lymphocytic, Chronic, B-Cell · Phase 1
- Leukemia, Monocytic, Acute · Phase 1
- Leukemia, Myeloid, Acute · Phase 1
- Leukemia, Myeloid, Chronic-Phase · Phase 1
- Leukemia, Myelomonocytic, Acute · Phase 1
- Leukemia, Myelomonocytic, Chronic · Phase 1
- Myelodysplastic Syndromes · Phase 1
- Neoplasms · Phase 1
- Neuroblastoma · Phase 1
- Precursor B-Cell Lymphoblastic Leukemia-Lymphoma · Phase 1
Mechanism of action
- DNA topoisomerase IIINHIBITOR
DNA topoisomerase II inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- sodium-(2-(4-(7-chloro-2-quinoxalinyloxy)phenoxy)propionate)
- xk469
- xk469
- xk469
- xk 469
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00095797 | Phase 1 | Oct 1, 2004 | National Cancer Institute (NCI), University of Texas at Houston |
| NCT00028548 | Phase 1 | Jan 1, 2002 | National Cancer Institute (NCI), Wayne State University |
| NCT00028522 | Phase 1 | Dec 1, 2001 | National Cancer Institute (NCI), University of Chicago |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Cancer Institute (NCI) | Government | 3 | 2 | 1 | 2001 |
| University of Chicago | Academic/Hospital | 1 | 0 | 1 | 2001 |
| University of Texas at Houston | Academic/Hospital | 1 | 0 | 1 | 2004 |
| Wayne State University | Academic/Hospital | 1 | 1 | 1 | 2002 |
4 organizations
Page 1 / 1